Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

Treatment with cisplatin (DDP) is one of the standard therapies used to treat non-small-cell lung cancer (NSCLC) and fundamentally causes resistance in cancer cells, which eventually poses as an obstacle to the efficacy of chemotherapy in NSCLC. Efforts are on all over the world to explore a sensiti...

Full description

Saved in:
Bibliographic Details
Main Authors: Bin Ke, Ting Wei, Yuanyuan Huang, Yuxin Gong, Gang Wu, Junfang Liu, Xiaoting Chen, Lin Shi
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2019/7241418
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2019/7241418

Similar Items